Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 496 to 510 of 666 results for kidney or kidneys or renal

  1. OCS Heart system for heart transplant (MIB86)

    NICE has developed a medtech innovation briefing (MIB) on OCS Heart system for heart transplant .

    Medtech innovation briefing
    Published
    29 November 2016

  2. Neonatal infection: antibiotics for prevention and treatment (NG195)

    This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.

    NICE guideline
    Last updated
    19 March 2024
    View recommendations

    Sections for NG195

  3. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

    Medtech innovation briefing
    Published
    29 November 2016

  4. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1098)

    Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.

    Technology appraisal guidance
    Published
    24 September 2025

    Sections for TA1098

  5. AccuVein AV400 for vein visualisation (MIB6)

    NICE has developed a Medtech Innovation Briefing (MIB) on the AccuVein AV400 for vein visualisation

    Medtech innovation briefing
    Published
    23 June 2014

  6. Percutaneous transluminal renal sympathetic denervation for resistant hypertension (IPG754)

    We have moved interventional procedures guidance 754 to become HealthTech guidance 662. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Laparoscopic renal denervation for loin pain haematuria syndrome (IPG709)

    We have moved interventional procedures guidance 709 to become HealthTech guidance 596. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. Frequency of monitoring: For adults, children and young people with CKD, what is the optimal monitoring frequency for albumin:creatinine ratio?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  9. Frequency of review: What is the most clinical and cost-effective frequency of review for children and young people with CKD?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  10. Renin–angiotensin–aldosterone system antagonists: For people aged over 75 years with CKD, what is the clinical effectiveness of renin–angiotensin–aldosterone system (RAAS) antagonists? [2014]

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  11. Treatment of ESA resistance in people on haemodialysis: What is the most effective type of intervention to treat people on haemodialysis with ESA‑resistant anaemia?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  12. Risk assessment, referral criteria and shared care: What is the association between risk factors and CKD outcomes in children and young people?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  13. Investigations for proteinuria: In children and young people, what is the accuracy of reagent strips for detecting albumin in urine?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  14. Managing anaemia: What are the long-term consequences of high ferritin levels (above 800 micrograms/litre) in children and young people with CKD?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  15. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued Reference number: GID-TA11421

    Technology appraisal guidance
    Discontinued